ACCESS PHARMACEUTICALS PROVIDES UPDATE ON PROLINDAC CLINICAL DEVELOPMENT PROGRAM

ENROLLING OVARIAN CANCER PATIENTS IN FRANCE; FINALIZING CLINICAL TRIAL PROGRAMS WITH PARTNERS IN CHINA AND KOREA

DALLAS, TX, August 3, 2009, ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), announced provided an update today on its clinical development strategy for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumors in human clinical studies. Access has commenced a new clinical study of ProLindac in France. The study will examine dose levels and regimens of ProLindac monotherapy in cancer patients, provide additional data to support design of combinations studies, and extend the safety database. Two ovarian cancer patients have been enrolled in the study to date, and it is anticipated 6 to 12 patients will be enrolled this year in advance of enrolling patients in trial evaluating ProLindac in combination with other chemotherapies. Access recently announced data from a recurrent ovarian cancer trial that showed that ProLindac was more active than currently available platinum drugs in that patient population, and that the drug w…… Read More

ACCESS PHARMACEUTICALS ANNOUNCES NEW MUGARD COMMERCIAL STRATEGY IN NORTH AMERICA

COMMENCE PRE-MARKETING ACTIVITIES WHILE SEEKING BIG PHARMA PARTNERSHIPS

DALLAS, TX, July 29, 2009, ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), announced today that it is evaluating strategic options for the commercialization of MuGard in North America. MuGard is an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy, and previously announced data suggest that the market for MuGard is significantly greater than previously expected. Frank Jacobucci, formerly President & CEO of Milestone Biosciences, has joined Access as a consultant, and will assist with ongoing reimbursement, manufacturing and commercial l…… Read More

ACCESS PHARMACEUTICALS ANNOUNCES COMMERCIAL LAUNCH OF MUGARD™ IN NORWAY BY SPEPHARM

EARLY MARKET ASSESSMENT STUDIES SUGGEST LARGER MARKET POTENTIAL

DALLAS, TX, July 27, 2009, ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), announced today that its European partner, SpePharm, has commenced commercial launch of MuGard in Norway. This follows previous commercial launches in the UK, Germany, Italy and Greece. Under a license from Access Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory approval and commercialization in the 27 countries of Europe. SpePharm plans to launch MuGard throughout Europe over the next 12 months, with di…… Read More

  • twitter
  • pitchengine
  • links

Access Pharmaceuticals, Inc. Recent Tweets

Follow Us On Twitter

Access Pharmaceuticals, Inc. Social Media Releases

MUGARD DATA FROM UK STUDY SHOWS PREVENTION OF ORAL MUCOSITIS IN HEAD AND NECK CANCER PATIENTS
Mugard shown effective in preventing oral mucositis in head and neck cancer patients undergoing radiation… Read More
Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
… Read More
Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
… Read More
ACCESS PHARMACEUTICALS ANNOUNCES COMMERCIAL LAUNCH OF MUGARD™ IN GREECE BY SPEPHARM
Access Pharmaceuticals' European Partner, SpePharm has commenced commercial launch of MuGard in Greece… Read More
ACCESS PHARMACEUTICALS CEO INTERVIEWED ON FINANCIAL WEBSITE
ACCP CEO interviewed on StockHaven.com. Call Offered Executive Summary and Perspective on Business Strategy.… Read More
ACCESS PHARMACEUTICALS ANNOUNCES INITIATION OF TWO NEW COBALAMIN™ ORAL INSULIN DRUG DELIVERY COLLABORATIONS
ACCESS PHARMACEUTICALS ANNOUNCES INITIATION OF TWO NEW COBALAMIN™ ORAL INSULIN DRUG DELIVERY COLLABORATIONS … Read More
ACCESS PHARMACEUTICALS ANNOUNCES GRANTING OF TWO US PATENTS FOR MUGARD™
ACCESS PHARMACEUTICALS ANNOUNCES GRANTING OF TWO US PATENTS FOR MUGARD™ http://pitch.pe/14806… Read More
ACCESS PHARMACEUTICALS ANNOUNCES PUBLICATION OF THIARABINE COMBINATION DATA
Thiarabine-clofarabine combination showed dramatically superior efficacy even at low doses.… Read More
Access Pharmaceuticals Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan
ProLindac Update: High DACH Platinum Activity; Drug Well Tolerated With No Signs of Acute Neurotoxicity… Read More
ACCESS PHARMACEUTICALS PROVIDES UPDATE ON GLOBAL LAUNCH OF MUGARD™
ACCESS PHARMACEUTICALS PROVIDES UPDATE ON GLOBAL LAUNCH OF MUGARD™:NEW FDA-APPROVED TREATMENT FOR ORAL MUCOSITIS… Read More

About Access Pharmaceuticals, Inc.

Access Pharmaceuticals (ACCP.ob) is an emerging pharmaceuticals company with a focus on oncology and diabetes. Access has one FDA approved treatment for oral mucositis (MuGard) which has been launched commercially in Europe and will be launched elsewhere in 2009. ProLindac, a novel DACH platinum chemotherapy, recently completed a Phase 2a trial in recurrent ovarian cancer and will enter combination trials shortly; ProLindac is partnered in the Far East and ACCP is actively seeking North American and European co-development partners. Additionally, ACCP has a novel nucleoside analogue, Thiarabine, which will enter Phase 2 leukemia trials this year, a preclinical stage monoclonal antibody (Angiolix) and additional preclinical oncology programs. Also, ACCP has an oral insulin and oral human growth hormone program which is being developed in a sponsored research agreement with a major pharmaceutical company (and for which ACCP is seeking additional development partnerships).